Abstract
Effective treatment options have greatly increased during the past 10 years for patients with progressive, radioiodine-refractory metastases from differentiated thyroid carcinoma. As clinical trials of potential new therapies were initiated, consensus definitions of “radioiodine-refractory” and “progressive” disease were required, which can be readily applied in routine clinical practice. Antiangiogenic drugs such as multitargeted kinase inhibitors have been extensively studied in phases II and III trials, demonstrating as a class of agents that this approach to treatment can provide significant improvement in progression-free survival. More selectively targeted therapies, aimed at kinases that signal along proliferation pathways, also may have a role to halt progression of disease. Of interest and now intensely studied is the observation that some selective kinase inhibitors may permit restoration of radioiodine responsiveness, thus providing a basis for reintroduction of radioiodine therapy. Finally, locally administered therapies such as stereotactic radiation and antiresorptive therapies can be valuable for management of skeletal metastases. Toxicities of these therapies can be considerable, but judicious and expectant management can permit patients to benefit from long-term stabilization of metastatic disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Haugen BR, Sherman SI. Evolving approaches to patients with advanced differentiated thyroid cancer. Endocr Rev. 2013;34:439–55.
Harris PJ, Bible KC. Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches. Expert Opin Investig Drugs. 2011;20:1357–75.
Janjan N, Lutz ST, Bedwinek JM, Hartsell WF, Ng A, Pieters Jr RS, et al. Therapeutic guidelines for the treatment of bone metastasis: a report from the American college of radiology appropriateness criteria expert panel on radiation oncology. J Palliat Med. 2009;12:417–26.
Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384:319–28.
Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. New Engl J Med. 2015;372:621–30.
Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada A, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol. 2012;13:897–905.
Dadu R, Devine C, Hernandez M, Waguespack SG, Busaidy NL, Hu MI, et al. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab. 2014;99:2086–94.
Brose MS, Cabanillas ME, Cohen EEW, Wirth L, Sherman SI, Riehl T, et al. An open-label, multi-center phase 2 study of the BRAF inhibitor vemurafenib in patients with metastatic or unresectable papillary thyroid cancer (PTC) positive for the BRAF V600 mutation. ECCO/ESMO/ESTRO annual meeting, Amsterdam; 2013.
Sherman SI. Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clin Oncol (R Coll Radiol). 2010;22:464–8.
Orita Y, Sugitani I, Toda K, Manabe J, Fujimoto Y. Zoledronic acid in the treatment of bone metastases from differentiated thyroid carcinoma. Thyroid. 2011;21:31–5.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Sherman, S.I. (2016). RAI-Refractory Differentiated Thyroid Cancer with Multiple Organ Progressive Disease. In: Cooper, D., Durante, C. (eds) Thyroid Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-22401-5_32
Download citation
DOI: https://doi.org/10.1007/978-3-319-22401-5_32
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-22400-8
Online ISBN: 978-3-319-22401-5
eBook Packages: MedicineMedicine (R0)